Improving Resection Rates Among African Americans With NSCLC
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
The burden to participants will be minimized to enhance retention. Patients in the usual care arm receive the current "gold standard" of treatment. The patients in the intervention arm are assigned to a PN, who helps to reduce the barriers to care that could negatively impact the patients' receipt of LDTCI. The telephone-administered survey is administered to all study participants at baseline and at 3-, 6-, and 12-months post-enrollment. It takes approximately 30-40 minutes to administer. The telephone mode of survey administration was chosen to reduce the number of visits that would be required by each patient. Interviews are scheduled at the convenience of the study participants. To further reduce burden to the study participants, the interviewers offer breaks during the interview process. Patients in both arms undergo standard therapy visits. Patients in the navigation arm receive standard therapy visits plus the navigation intervention. Outside of the standard therapy visits, no additional clinic visits are required of the study participants.
Once informed consent has been obtained and the informed consent document is received, the SSC/PN will communicate to the MUSC HCC study staff the participant's contact information and that the participant is ready for baseline survey administration. All the study surveys will be administered by trained MUSC HCC study staff via telephone. A survey answer guide will be provided to the participant either in-person or via mail prior to administration of the baseline survey.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Delaware
-
Lewes, Delaware, Estados Unidos, 19958
- Beebe Healthcare Tunnell Cancer Center
-
-
Georgia
-
Savannah, Georgia, Estados Unidos, 31405
- Saint Joseph's/Candler Hospital
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Stroger Hospital of Cook County
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner NCORP
-
-
Michigan
-
Royal Oak, Michigan, Estados Unidos, 48073
- Beaumont Hospital - Royal Oak
-
-
Minnesota
-
Saint Louis Park, Minnesota, Estados Unidos, 55426
- Metro-Minnesota NCORP
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- Nevada Cancer Research Foundation
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27127
- Wake Forest University Health Sciences
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Fox Chase
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Virginia Commonwealth University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- AA race
- Clinically suspicious or biopsy-proven, early stage NSCLC, and
- Ages 21 years and older
Exclusion Criteria:
- Previous history of lung cancer
- Spread of newly diagnosed probably/proven lung cancer to other part of the body
- Diagnosis of synchronous cancer other than non-melanoma skin cancer or lung cancer, and
- Receipt of surgical resection or radiosurgery for lung cancer since diagnosis with probable/proven lung cancer
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Usual Care Arm
Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
|
Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
|
|
Experimental: Intervention Arm
The PN will provide each patient with a copy of the NCI's "What You Need to Know About Lung Cancer" booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options. The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first). During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum). |
The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis.
Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Receipt of LDTCI
Prazo: 12 Months Post-Enrollment
|
Receipt of lung-directed therapy with curative intent (LDTCI), Inquiry at time of follow-up survey, confirmed by medical record review
|
12 Months Post-Enrollment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Receipt of Surgical and/or Radiation Oncology Consultation Confirmed by Medical Record Review
Prazo: Baseline, 3, 6, 9, and 12 Months Post-Enrollment
|
• Receipt of surgical and/or radiation oncology consultation (defined as outpatient or inpatient consultation with a general or cardiothoracic surgeon and/or radiation oncologist to discuss LDTCI for NSCLC within 4 months post-diagnosis of probable/proven, early stage NSCLC).
|
Baseline, 3, 6, 9, and 12 Months Post-Enrollment
|
|
Time to LDTCI (For Pts. Who Received LDTCI Only) Confirmed by Medical Record Review
Prazo: Baseline, 3, 6, 9, and 12 Months Post-Enrollment
|
Time to LDTCI (For Pts.
Who Received LDTCI Only).
Inquiry at Time of Follow-Up Survey, Confirmed by Medical Record Review.
Baseline, 3, 6, 9, and 12 Months Post-Enrollment
|
Baseline, 3, 6, 9, and 12 Months Post-Enrollment
|
|
Satisfaction with Care Received, Patient Satisfaction(REF) (28 items)
Prazo: 6 Months Post-Enrollment
|
Satisfaction with Care Received, Patient Satisfaction(REF) (28 items).
6 Months Post-Enrollment
|
6 Months Post-Enrollment
|
|
Time of Death, Follow-up Survey, Confirmed by Medical Record Review
Prazo: Baseline, 3, 6, 9, and 12 Months Post-Enrollment
|
Time of Death.
Inquiry at Time of Follow-Up Survey, Confirmed by Medical Record Review , inquiry of cancer registries at study sites, and inquiry of Social Security Death Index.
Baseline, 3, 6, 9, and 12 Months Post-Enrollment.
|
Baseline, 3, 6, 9, and 12 Months Post-Enrollment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kathryn E Weaver, PhD, Wake Forest Universith Health Sciences
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRB00031268
- REBAWF 01414 (Outro identificador: NCI)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .